一种自催化NO/O2气释放纳米酶,通过血管正常化和低氧缓解进行放射治疗敏感化
Shuyu Wang1, Miaomiao Cheng1, Shenghui Wang1
1Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
Advanced materials (Deerfield Beach, Fla.)
|August 5, 2024
概括
一个新的纳米酶系统为瘤提供氧化 (NO) 和氧 (O2),克服缺氧并增强癌症放射治疗. 这种方法针对瘤,增强辐射敏感性,并可能减少放射治疗的副作用.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 放射治疗 (RT) 对癌症治疗至关重要,但受到瘤缺氧的限制,导致放射电阻.
- 瘤缺氧创造了一个具有挑战性的微环境,降低了传统癌症治疗的有效性.
研究的目的:
- 开发一种瘤向的纳米酶系统,能够产生氧化 (NO) 和氧气 (O2),以克服瘤缺氧.
- 为了增强瘤的辐射敏感性和提高放射治疗的疗效.
主要方法:
- 设计了一个"假肢-阿尔金因"联合组装的纳米酶系统 (HRRu-HFn),集成氧化合成酶 (NOS) 和催化酶 (CAT) 功能.
- 表面修改的纳米酶与人类重链费里丁 (HFn) 增强瘤向.
- 利用内源性过氧化来触发瘤微环境 (TME) 内的自主O2和NO释放.
主要成果:
- HRRu-HFn纳米酶成功地在TME中产生了NO和O2,减轻了缺氧.
- 这些纳米酶使瘤血管正常化,并改善了血液 perfusion.
- 在食道状细胞癌模型中表现出增强的辐射敏感性.
结论:
- HRRu-HFn纳米酶系统有效地对抗瘤缺氧,并强化放射治疗.
- 这种方法显示了降低辐射剂量和尽量减少副作用的潜力.
- 纳米酶对NO和O2的有针对性的输送为改善癌症治疗结果提供了一个有希望的策略.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Electron Transport Chain: Complex I and II
12.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.5K


